huIL5RA Mouse
제품명
huIL5RA Mouse
제품 ID
C002007
품종 계통
C57BL/6NCya-Il5ratm1(hIL5RA)/Cya
Backgroud
C57BL/6NCya
상태
이 마우스 계통을 논문에서 사용할 경우, “huIL5RA Mouse (카탈로그 번호 C002007)은 Cyagen에서 구입하였습니다.”라고 명시해 주시기 바랍니다.
구매 가능한 제품 종류
연령
Genotype
성별
수량
유전자명
유전자 별칭
IL5R, CD125, CDw125, HSIL5R3
NCBI ID
염색체
Chr 3
MGI ID
Datasheet
품종 계통 설명
The IL5RA gene encodes the interleukin-5 receptor subunit alpha (IL5RA), the receptor subunit that specifically binds IL5. It is primarily expressed on eosinophils, basophils, and their progenitor cells, with low expression levels in most normal tissues [1]. IL5RA plays a critical role in the proliferation, differentiation, survival, recruitment, and activation of eosinophils. Upon binding to IL5, it activates downstream signaling pathways such as JAK2-STAT5, thereby promoting type 2 inflammatory responses. Excessive activation of the IL5/IL5RA axis in cells or tissues can lead to eosinophil expansion and tissue infiltration, exacerbating inflammation and tissue damage [2]. IL5RA exerts a central regulatory role in the pathogenesis of eosinophil-related inflammatory diseases, including severe eosinophilic asthma (SEA), chronic rhinosinusitis with nasal polyps (CRSwNP), and eosinophilic granulomatosis with polyangiitis (EGPA) [3-5]. Studies have shown that abnormal IL5RA expression is causally associated with the genetic risk of multiple myeloma (MM), positioning it as a potential tumor biomarker and therapeutic target [6]. Humanized anti-IL5RA CAR-T cell therapy can effectively deplete eosinophils and their precursors at various developmental stages in the bone marrow and peripheral blood [1]. Currently, multiple clinical drugs targeting the IL-5/IL5RA pathway have been approved or are under development, including mepolizumab, reslizumab, and benralizumab [7-8].
The huIL5RA mouse was generated by replacing the mouse Il5ra endogenous extracellular domain with the human IL5RA extracellular domain. The murine transmembrane-cytoplasmic region was preserved. huIL5RA mice can be used for the research and development as well as preclinical pharmacological and efficacy evaluation of IL5RA-targeted drugs for multiple eosinophil-related inflammatory diseases, including severe eosinophilic asthma (SEA), chronic rhinosinusitis with nasal polyps (CRSwNP), and eosinophilic granulomatosis with polyangiitis (EGPA), as well as multiple myeloma (MM).
Reference
Wu Y, Zhang R, Sun B, et al. IL-5 CAR-T cell therapy induces effective remission in hypereosinophilic disorders. J Hematol Oncol. 2026;19(1):18.
Chen S, Chen G, Xu F, et al. Treatment of allergic eosinophilic asthma through engineered IL-5-anchored chimeric antigen receptor T cells. Cell Discov. 2022;8(1):80.
Buchheit KM, Shaw D, Chupp G, et al. Interleukin-5 as a pleiotropic cytokine orchestrating airway type 2 inflammation: Effects on and beyond eosinophils. Allergy. 2024;79(10):2662-2679.
Hanania NA, Herth FJF. Persistent airway obstruction in severe eosinophilic asthma: targeting interleukin-5 and eosinophils. Eur Respir Rev. 2025;34(178):250024.
Bettiol A, Urban ML, Padoan R, et al. Benralizumab for eosinophilic granulomatosis with polyangiitis: a retrospective, multicentre, cohort study. Lancet Rheumatol. 2023;5(12):e707-e715.
Went M, Duran-Lozano L, Halldorsson GH, et al. Deciphering the genetics and mechanisms of predisposition to multiple myeloma. Nat Commun. 2024;15(1):6644.
Lombardi C, Comberiati P, Ridolo E, et al. Anti-IL-5 Pathway Agents in Eosinophilic-Associated Disorders Across the Lifespan. Drugs. 2024;84(6):661-684.
Fricker M, Harrington J, Hiles SA, Gibson PG. Mepolizumab depletes inflammatory but preserves homeostatic eosinophils in severe asthma. Allergy. 2024;79(11):3118-3128.
변형 전략
The mouse Il5ra endogenous extracellular domain was replaced with the human IL5RA extracellular domain. The murine transmembrane-cytoplasmic region was preserved.
Figure 1. Gene editing strategy of huIL5RA mice.
응용 분야
Screening, development, and preclinical evaluation of IL-5RA-targeted drugs;
Mechanistic studies of chronic rhinosinusitis with nasal polyps (CRSwNP);
Mechanistic studies of severe eosinophilic asthma (SEA);
Mechanistic studies of eosinophilic granulomatosis with polyangiitis (EGPA);
Mechanistic studies of allergic inflammation;
In vivo validation of immunotherapies;
Research on cytokine signaling pathways.
문의하기
맞춤형 동물 모델 관련 상담을 위해 Cyagen 전문가와 연락해 보세요. 아래 양식을 작성하여 상담을 시작하거나 견적을 요청하시기 바랍니다.
Cyagen은 고객님의 개인정보를 소중히 여깁니다. 최신 제품, 서비스 및 인사이트를 안내드리고자 합니다. 고객님의 수신 설정은 다음과 같습니다:
해당 커뮤니케이션은 언제든지 수신 거부하실 수 있습니다. 수신 거부 방법 및 데이터 보호에 대한 자세한 내용은 개인정보처리방침을 참고해 주시기 바랍니다.
아래 버튼을 클릭함으로써, 요청하신 콘텐츠 제공을 위해 본 양식을 통해 제출된 개인정보를 Cyagen이 저장 및 처리하는 데 동의하게 됩니다.